designed a biomimetic tau‐nanochaperone (Tau‐nChap) with tau‐targeting ability for AD treatment (Figure 7a).[223] VQIINK, derived from the tau sequence, is a strong driving force for tau aggregation and NFT formation, showing selective binding to pathological tau. Here, MAPT is linked to Alzheimer disease.